UPDATE 2-US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10 Tue, May 7, 2024, 3:51 PM GMT+2 1 min read 0 In this article: Advertisement Up next 1 High-Growth Tech Stock Set to S...
UiPath, Inc. Class A (PATH)
Company Research
Source: Acquire Media Monitor
FDA advisers will discuss its experimental Alzheimer's disease drug, donanemab, on June 10. Donanemab has faced two separate regulatory delays in the United States, while a similar therapy by Eisai and partner Biogen, called Leqembi, received the U.S. Food and Drug Administration's approval last year. Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its approval. Before approving Leqembi, which belongs to the same class of treatment as donanemab, the FDA had also conducted a meeting of an independent panel. Lilly's donanemab, administered via once-a-month infusions, is designed to clear a toxic Alzheimer's-linked protein called beta amyloid from the brain. In clinical trials, the treatment slowed the progression of memory and thinking problems by 22% to 29% overall, roughly comparable to the 27% slowing seen with Leqembi. In patients
Show less
Read more
Impact Snapshot
Event Time:
PATH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PATH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PATH alerts
High impacting UiPath, Inc. Class A news events
Weekly update
A roundup of the hottest topics
PATH
News
- UiPath (PATH) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]Yahoo! Finance
- 3 Little-Known Stocks That Could Provide Monster Returns [Yahoo! Finance]Yahoo! Finance
- Prediction: This Will Be UiPath's Next Big Move [Yahoo! Finance]Yahoo! Finance
- UiPath Kicks Off Annual AI25 Awards to Recognize the Most Innovative Uses of AI and Business Automation [Yahoo! Finance]Yahoo! Finance
- UiPath Kicks Off Annual AI25 Awards to Recognize the Most Innovative Uses of AI and Business AutomationBusiness Wire
PATH
Earnings
- 3/13/24 - Beat
PATH
Sec Filings
- 5/17/24 - Form 4
- 5/10/24 - Form 8-K
- 5/10/24 - Form ARS
- PATH's page on the SEC website